Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte ...
October 03 2018 - 7:30AM
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of immunotherapies for cancer and stem cell therapies
for degenerative diseases, today announced it has entered into a
Patent License Agreement (the “License Agreement”) with the
National Cancer Institute (“NCI”), an institute of the National
Institutes of Health, within the Department of Health and Human
Services. Pursuant to the License Agreement, NCI granted CBMG a
non-exclusive, sub-licensable worldwide license to develop,
manufacture and commercialize next generation neoantigen-reactive
tumor infiltrating lymphocyte (“TIL”) technology to treat a variety
of cancers.
“We are extremely pleased to finalize this
License Agreement as this next generation TIL technology will
fortify our clinical development pipelines for solid tumors.
It is a significant extension of our CAR/TCR-T pipelines against
solid tumors in the immuno-oncology platform,” stated Tony (Bizuo)
Liu, Chief Executive Officer of CBMG. “The medical oncology
community is very aware of the innovative work using T cell-based
immunotherapy and autologous TIL transfer for the treatment of
various cancers. We look forward to continuing to advance this
field.”
About Cellular Biomedicine
GroupCellular Biomedicine Group, Inc. (NASDAQ: CBMG)
develops proprietary cell therapies for the treatment of cancer and
degenerative diseases. We conduct immuno-oncology and stem cell
clinical trials in China using products from our integrated GMP
laboratory. Our GMP facilities in China, consisting of 12
independent cell production lines, are designed and managed
according to both China and U.S. GMP standards. Our Shanghai
facility includes a ”Joint Laboratory of Cell Therapy” with GE
Healthcare and a “Joint Cell Therapy Technology Innovation and
Application Center” with Thermo Fisher Scientific, whose
partnerships focus on improving manufacturing processes for cell
therapies. The CBMG pipeline includes preclinical compounds
targeting CD20-, CD22- and B-cell maturation antigen
(BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and
tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial
in China for Rejoin® autologous Human Adipose-derived
Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee
Osteoarthritis (KOA) as well as a Phase I trial in China for
AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the treatment of KOA
are ongoing. CBMG is included in the broad-market Russell 3000®
Index and the small-cap Russell 2000® Index, and the Loncar China
BioPharma index. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts and may be forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking information is inherently subject to risks
and uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include those regarding our ability to implement our plans,
strategies and objectives for future operations, including
regulatory approval of our IND applications, our plan to configure
part of our Shanghai facility with GE Healthcare’s FlexFactory
platform, our ability to execute on our obligations under the terms
of our licensing and collaboration arrangement with Novartis, our
ability to execute on proposed new products, services or
development thereof, results of our clinical research and
development, regulatory infrastructure governing cell therapy and
cellular biopharmaceuticals, our ability to enter into agreements
with any necessary manufacturing, marketing and/or distribution
partners for purposes of commercialization, our ability to seek
intellectual property rights for our product candidates,
competition in the industry in which we operate, overall market
conditions, any statements or assumptions underlying any of the
foregoing and other risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as “may,” “will,” “expects,” “plans,”
“intends,” “estimates,” “potential,” or “continue,” or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts: Sarah Kelly Director of
Corporate Communications, CBMG+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024